What kind of business does Jin Wan Lin operate?

Jin Wan Lin develops and provides reagent kits utilizing genomic analysis technology, expanding its business in the medical field.

What is whole genome sequencing?

Whole genome sequencing is the process of determining the complete DNA sequence of an organism's genome. It is useful for understanding disease causes and personalized medicine.

What does this contract mean for Jin Wan Lin?

This large contract with a national hospital serves as proof of the company's technological capabilities and reliability, and is expected to significantly contribute to future business expansion and revenue growth.

What is the future outlook for the genomic analysis reagent market?

With the advancement of genomic medicine, the demand for high-precision genomic analysis reagents is expected to continue increasing, indicating an expanding market.

What are Jin Wan Lin's future prospects?

Leveraging this contract, the company is likely aiming to become a leading player in the genomics field through further collaborations with public institutions and expansion into the private market.

AI News NQ Analysis

[Jin Wan Lin - Creation] Announcement: Company Receives Bid for "Whole Genome Sequencing Test Kit Reagent Set" from a National Hospital

NQ Score 8/100

N1 Content Completeness 0.9

AI Summary (NQ-processed)

Jin Wan Lin (Jin Wan Lin - Creation) has received a bid for the "Whole Genome Sequencing Test Kit Reagent Set" from a national hospital. The awarded amount is NT$110,000,000, with the contract period running from June 10, 2026, to December 31, 2028. This contract is expected to expand the company's business and increase revenue.

AI Analysis

Frequently Asked Questions

Q: What kind of business does Jin Wan Lin operate?: A: Jin Wan Lin develops and provides reagent kits utilizing genomic analysis technology, expanding its business in the medical field.
Q: What is whole genome sequencing?: A: Whole genome sequencing is the process of determining the complete DNA sequence of an organism's genome. It is useful for understanding disease causes and personalized medicine.
Q: What does this contract mean for Jin Wan Lin?: A: This large contract with a national hospital serves as proof of the company's technological capabilities and reliability, and is expected to significantly contribute to future business expansion and revenue growth.
Q: What is the future outlook for the genomic analysis reagent market?: A: With the advancement of genomic medicine, the demand for high-precision genomic analysis reagents is expected to continue increasing, indicating an expanding market.
Q: What are Jin Wan Lin's future prospects?: A: Leveraging this contract, the company is likely aiming to become a leading player in the genomics field through further collaborations with public institutions and expansion into the private market.